KR20090119768A - 흑색종 치료법 - Google Patents

흑색종 치료법 Download PDF

Info

Publication number
KR20090119768A
KR20090119768A KR1020097018743A KR20097018743A KR20090119768A KR 20090119768 A KR20090119768 A KR 20090119768A KR 1020097018743 A KR1020097018743 A KR 1020097018743A KR 20097018743 A KR20097018743 A KR 20097018743A KR 20090119768 A KR20090119768 A KR 20090119768A
Authority
KR
South Korea
Prior art keywords
melanoma
compound
formula
reaction
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097018743A
Other languages
English (en)
Korean (ko)
Inventor
칼라 씨. 하이즈
폴 홀렌바흐
다니엘 메네제스
낸시 프리어
캐써린 렌달
마리온 비스만
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39500684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090119768(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20090119768A publication Critical patent/KR20090119768A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097018743A 2007-03-09 2008-03-07 흑색종 치료법 Withdrawn KR20090119768A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89404607P 2007-03-09 2007-03-09
US60/894,046 2007-03-09
US91140607P 2007-04-12 2007-04-12
US60/911,406 2007-04-12

Publications (1)

Publication Number Publication Date
KR20090119768A true KR20090119768A (ko) 2009-11-19

Family

ID=39500684

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097018743A Withdrawn KR20090119768A (ko) 2007-03-09 2008-03-07 흑색종 치료법

Country Status (11)

Country Link
US (1) US20100086518A1 (enExample)
JP (1) JP2010520881A (enExample)
KR (1) KR20090119768A (enExample)
AU (1) AU2008226582B2 (enExample)
BR (1) BRPI0808714A2 (enExample)
CA (1) CA2679268A1 (enExample)
CL (1) CL2008000681A1 (enExample)
MX (1) MX2009009574A (enExample)
RU (1) RU2009136669A (enExample)
TW (1) TW200843766A (enExample)
WO (1) WO2008112509A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
TWI410418B (zh) 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
US20120064008A1 (en) * 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
US8551479B2 (en) * 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
TR201810944T4 (tr) 2013-10-25 2018-08-27 Novartis Ag Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
WO2016053249A1 (en) 2014-09-29 2016-04-07 Hewlett-Packard Development Company, L.P. Hinge assembly with compressible sleeve
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3103450A1 (en) 2015-06-12 2016-12-14 Friedrich-Alexander-Universität Erlangen-Nürnberg None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CN108610293B (zh) * 2018-06-15 2020-08-04 南京工业大学 一种采用微通道反应装置制备多韦替尼中间体的方法
WO2024097855A2 (en) * 2022-11-03 2024-05-10 University Of Florida Research Foundation, Incorporated Identification of small molecules that recruit and activate rnase l

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511616A (ja) * 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
EP2762475A1 (en) * 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
EP2368566A1 (en) * 2006-07-13 2011-09-28 ZymoGenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
EP2049904A1 (en) * 2006-07-28 2009-04-22 Novartis Ag Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma

Also Published As

Publication number Publication date
US20100086518A1 (en) 2010-04-08
CL2008000681A1 (es) 2008-10-24
RU2009136669A (ru) 2011-04-20
BRPI0808714A2 (pt) 2014-08-12
JP2010520881A (ja) 2010-06-17
WO2008112509A1 (en) 2008-09-18
AU2008226582B2 (en) 2011-07-21
MX2009009574A (es) 2009-09-16
TW200843766A (en) 2008-11-16
CA2679268A1 (en) 2008-09-18
AU2008226582A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
AU2008226582B2 (en) Treatment of melanoma
ES2486240T3 (es) Sales de lactato de compuestos de quinolinona y su uso farmacéutico
KR20050075005A (ko) 암을 치료하는 방법 및 관련 방법
US20100173873A1 (en) Treatment of metastasized tumors
KR20080007443A (ko) ｃ-ＭＥＴ 자기 인산화 저해 작용을 갖는 티에노피리딘유도체, 퀴놀린 유도체, 및 퀴나졸린 유도체
AU2006247803B2 (en) Methods for treating drug resistant cancer
WO2022005961A1 (en) Prpk inhibitors
JP2021527071A (ja) Ｅｐａｃ阻害剤としてのチエノ［２，３−ｂ］ピリジン誘導体及びその医薬用途
CN101641097A (zh) 黑素瘤的治疗
EP2864332B1 (en) Imidazo bicyclic imminium compounds as antitumor agents
HK1155664B (en) Treatment of metastasized tumors
KR20120038677A (ko) 신규 히드록사믹산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물
HK1118538A (en) Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090908

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid